Fibrate treatment can increase serum creatinine levels [4]

Nephrology Dialysis Transplantation

Volumn 16, Issue 6, 2001, Pages 1301-

  Tsimihodimos, V ^a   Kakafika, A ^a   Elisaf, M ^a  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BEZAFIBRATE; CIPROFIBRATE; CREATININE; CYCLOOXYGENASE 2; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PROSTAGLANDIN; UREA;

CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG MECHANISM; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LETTER; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; RECIPIENT; RETROSPECTIVE STUDY; UNIVERSITY HOSPITAL; UREA BLOOD LEVEL;

ANTILIPEMIC AGENTS; CLOFIBRIC ACID; CREATININE; GEMFIBROZIL; HUMANS; KIDNEY DISEASES; PROCETOFEN; UREA;

EID: 0034970314     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/16.6.1301     Document Type: Letter

References (5)

1. Fibrate-induced increase in blood urea and creatinine: Is gemfibrozil the only innocuous agent?
2. Altered hepatic eicosanoid concentrations in rats treated with the peroxisome proliferators ciprofibrate and perfluorodecanoic acid
3. Induction of cyclooxygenase-2 expression by peroxisome proliferators and non-tetradecanoylphorbol 12, 13-myristate-type tumor promoters in immortalized mouse liver cells
4. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferators by coactivator-dependent receptor ligand assay
5. Effect of gemfibrozil on serum levels of prostacyclin and precursor fatty acids in hyperlipidemic patients with type 2 diabetes